Evidence map›Paper›PMID 41625068›Full record

ArticleFrontiers in bioengineering and biotechnology2025

FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway.

Zhicheng Hu, Fan Li, Chunyi Hu, Qiongdan Shan, Zhouhao Tang, Meifan Jiang, Xiaojing Yi, Xixi Chen, Litai Jin, Xu Wang and 1 more

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhicheng Hu *School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Fan Li *School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Chunyi HuSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Qiongdan ShanSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Zhouhao TangSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Meifan JiangSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Xiaojing YiSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Xixi ChenDepartment of Pharmacy, Taizhou Central Hospital, Taizhou, Zhejiang, China.
Litai JinSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Xu WangSchool of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, China.
Yang WangDepartment of Histology and Embryology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Endothelial cell dysfunction during aging is a key driver of vascular aging and related diseases; however, effective strategies to selectively eliminate senescent endothelial cells and restore vascular function remain lacking. FOXO4-DRI, a novel peptide-based intervention, specifically disrupts the interaction between FOXO4 and P53, thereby inducing apoptosis in senescent cells. This study innovatively focuses on the mechanism by which FOXO4-DRI induces apoptosis in senescent endothelial cells, demonstrating that it functions by activating the p53/BCL-2/Caspase-3 signaling pathway to promote selective apoptosis of these cells. FOXO4-DRI significantly improves vascular function and delays vascular aging. These findings not only enrich the molecular understanding of senescent cell clearance but also provide a novel strategy for precise targeting of endothelial cell senescence in therapeutic applications. Materials and methods: This study aims to analyze the vascular function and aging status of the aorta in naturally aged mice and progeroid model mice following FOXO4-DRI injection. Additionally, it investigates changes in endothelial cell function in senescent endothelial cells induced by oxygen-glucose deprivation (OGD), as well as the protein expression and interaction in the FOXO4-P53 signaling pathway. To assess the impact of FOXO4-DRI on endothelial cell senescence, the senescent endothelial cells were treated with FOXO4-DRI, followed by immunofluorescence and Western blotting experiments. Results: Injection of FOXO4-DRI in both naturally aged and induced aging mice effectively suppressed aortic aging and improved aortic function. Additionally, we found that FOXO4-DRI alleviates endothelial cell senescence induced by OGD, thereby enhancing endothelial cell function. Through co-immunoprecipitation (CO-IP) experiments, we discovered that FOXO4-DRI prevents the binding of FOXO4 to P53, facilitating the phosphorylated P53 nuclear exclusion, which subsequently trigger BAX and cleaved caspase-3, leading to the apoptosis of senescent cells. Ultimately, this mechanism achieves the goal of inhibiting vascular aging. Conclusion: FOXO4-DRI promotes the nuclear export of phosphorylated P53 by inhibiting the binding of FOXO4 to P53 in endothelial cells, thereby facilitating the apoptosis of senescent endothelial cells and alleviating aging.

Indexed as

D-Galendothelial cell senescenceFOXO4-DRIP53ROS

Identifiers

PMID41625068
PMCPMC12852416

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.